FY2030 EPS Estimates for Scholar Rock Increased by Analyst

Scholar Rock Holding Corporation (NASDAQ:SRRK) – Equities researchers at HC Wainwright raised their FY2030 EPS estimates for shares of Scholar Rock in a research note issued to investors on Tuesday, March 3rd. HC Wainwright analyst A. Maldonado now forecasts that the company will earn $1.26 per share for the year, up from their prior forecast of $1.07. HC Wainwright currently has a “Buy” rating and a $58.00 price target on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($2.42) per share.

Scholar Rock (NASDAQ:SRRK) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.10. During the same period last year, the company earned ($0.64) earnings per share.

SRRK has been the topic of a number of other reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Scholar Rock in a research note on Thursday, December 11th. Raymond James Financial reiterated a “strong-buy” rating on shares of Scholar Rock in a research report on Tuesday. JPMorgan Chase & Co. upped their target price on shares of Scholar Rock from $46.00 to $47.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. Truist Financial lifted their price target on Scholar Rock from $44.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Barclays increased their price objective on Scholar Rock from $52.00 to $53.00 and gave the stock an “overweight” rating in a report on Tuesday. Four analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Scholar Rock presently has an average rating of “Buy” and a consensus target price of $54.14.

Scholar Rock Trading Down 2.7%

Shares of NASDAQ SRRK opened at $46.15 on Thursday. Scholar Rock has a 12-month low of $22.71 and a 12-month high of $49.82. The company has a market cap of $5.30 billion, a price-to-earnings ratio of -13.45 and a beta of 0.70. The company has a current ratio of 6.95, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. The stock’s 50 day simple moving average is $45.33 and its 200 day simple moving average is $39.19.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SRRK. Invesco Ltd. lifted its position in shares of Scholar Rock by 21.0% during the 4th quarter. Invesco Ltd. now owns 82,462 shares of the company’s stock valued at $3,632,000 after acquiring an additional 14,291 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Scholar Rock during the fourth quarter worth $308,000. Mackenzie Financial Corp purchased a new stake in shares of Scholar Rock during the fourth quarter valued at $221,000. Empowered Funds LLC acquired a new position in shares of Scholar Rock in the 4th quarter valued at $114,000. Finally, KVP Capital Advisors LP acquired a new position in shares of Scholar Rock in the 4th quarter valued at $1,982,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

Insider Activity at Scholar Rock

In other Scholar Rock news, CEO David Hallal sold 57,450 shares of the company’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $42.70, for a total value of $2,453,115.00. Following the completion of the sale, the chief executive officer directly owned 1,541,645 shares of the company’s stock, valued at approximately $65,828,241.50. This represents a 3.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Keith Woods sold 16,746 shares of the business’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total transaction of $715,054.20. Following the completion of the sale, the chief operating officer owned 583,254 shares in the company, valued at $24,904,945.80. The trade was a 2.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 208,470 shares of company stock worth $9,201,778 in the last quarter. Company insiders own 13.30% of the company’s stock.

Key Headlines Impacting Scholar Rock

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: Major analysts raised ratings and targets — BMO bumped its target to $70 (Outperform), Citigroup raised its target to $58 (Buy) and Piper Sandler lifted its target to $58 (Overweight), signaling fresh upside expectations. Analyst Price Target Raises Piper Sandler Note
• Positive Sentiment: HC Wainwright raised its FY2030 EPS forecast to $1.26 (from $1.07) and reiterated a Buy rating with a $58 price target — a bullish long‑term earnings view that contrasts with current street estimates. HC Wainwright Upgrade
• Positive Sentiment: Scholar Rock reported progress on apitegromab: management outlined a 2026 BLA resubmission plan and commercial launch preparations following favorable interactions with the FDA — this is the primary operational catalyst for upside if approval and launch proceed. FDA / BLA Progress
• Neutral Sentiment: Q4 2025 results marginally beat expectations (EPS about -$0.88 vs. consensus ~ -$0.8825), showing stability but not a strong inflection in near‑term profitability. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Street consensus still expects a negative EPS for the current fiscal year (≈ -$2.42), underlining that near‑term earnings and cash‑flow risk remain until apitegromab is approved and commercialized. Consensus EPS Context

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).